Bibliographic Details
| Title: |
NM101 Phase III study of NE3107 in Alzheimer's disease: rationale, design and therapeutic modulation of neuroinflammation and insulin resistance. |
| Authors: |
Reading CL; BioVie, Inc., San Diego, CA 92122, USA., Ahlem CN; BioVie, Inc., San Diego, CA 92122, USA., Murphy MF; Worldwide Clinical Trials, Morrisville, NC 27560, USA. |
| Source: |
Neurodegenerative disease management [Neurodegener Dis Manag] 2021 Aug; Vol. 11 (4), pp. 289-298. Date of Electronic Publication: 2021 Jul 12. |
| Publication Type: |
Clinical Trial Protocol; Journal Article |
| Journal Info: |
Publisher: Taylor & Francis Country of Publication: England NLM ID: 101517977 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1758-2032 (Electronic) Linking ISSN: 17582024 NLM ISO Abbreviation: Neurodegener Dis Manag Subsets: MEDLINE |
| Database: |
MEDLINE Ultimate |
